You are here

Coronary Intervention & Surgery

 

Future heart stents could be coated with the popular erectile dysfunction drug Viagra as a way to prevent blood clots and the narrowing of arteries, new research suggests.

It’s logical that frailty factors into recovery from major heart surgery. But what, exactly, is the best method for judging a patient’s frailty before transcatheter or surgical aortic valve replacement (TAVR/SAVR)? A study published online July 7 in the Journal of the American College of Cardiology explored this question by examining seven frailty scales in predicting poor outcomes.

New manufacturing methods can further personalize medicine—and now 3D printing may offer cardiologists a method of testing transcatheter aortic valve replacements (TAVR) for leakage before implantation.

New research on a heart pump designed to treat cardiogenic shock patients receiving a percutaneous coronary intervention (PCI) suggests that early placement of the device can boost survival rates.

An experimental transcatheter device by Canada-based Neovasc, used to treat mitral regurgitation, was shown to be effective in treating a patient with several severe heart conditions.

 

Recent Headlines

Heart stents could soon get an added boost: Viagra

Future heart stents could be coated with the popular erectile dysfunction drug Viagra as a way to prevent blood clots and the narrowing of arteries, new research suggests.

Medtronic’s TAVR platform approved for expanded use by FDA

The U.S. Food and Drug Administration (FDA) has approved the use of a self-expanding transcatheter aortic valve replacement (TAVR) platform on patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery.

Want to predict mortality in elderly TAVR, SAVR patients? Use this four-item scale

It’s logical that frailty factors into recovery from major heart surgery. But what, exactly, is the best method for judging a patient’s frailty before transcatheter or surgical aortic valve replacement (TAVR/SAVR)? A study published online July 7 in the Journal of the American College of Cardiology explored this question by examining seven frailty scales in predicting poor outcomes.

3D-printed models could predict leakage location, severity in TAVR

New manufacturing methods can further personalize medicine—and now 3D printing may offer cardiologists a method of testing transcatheter aortic valve replacements (TAVR) for leakage before implantation.

Early placement of Abiomed's Impella 2.5 increases survival rate in cardiogenic shock patients

New research on a heart pump designed to treat cardiogenic shock patients receiving a percutaneous coronary intervention (PCI) suggests that early placement of the device can boost survival rates.

TVT2017: 4C MR therapy could be safer than other TMVR approaches

A new mitral regurgitation (MR) therapy designed to treat patients with structural heart disease was shown to be a safer treatment option than other transcatheter mitral valve replacement (TMVR) in a presentation at this year’s Transcatheter Valve Therapies (TVT) conference in Chicago.

TVT2017: Experimental transcatheter device yields consistent, positive outcomes for patients

An experimental transcatheter device by Canada-based Neovasc, used to treat mitral regurgitation, was shown to be effective in treating a patient with several severe heart conditions.

Bacteria in open-heart surgery device more common than scientists thought

A new study presented this week at a global conference in Portland, Oregon, revealed that a significant number of heater-cooler units tested positive for bacteria associated with fatal infections in open-heart surgery patients.

Blacks with MI have higher mortality rates after ambulance diversion

Plenty of research has been devoted to examining disparities in outcomes for racial minorities. A new study, published in the June issue of Health Affairs, examined the role of emergency department (ED) crowding and ambulance diversion for blacks and whites experiencing MI.

FDA approves Sentinel device from Claret to reduce stroke during TAVR

In a June 5 release, Claret Medical announced it had received regulatory clearance from the U.S. Food and Drug Administration for its Sentinel Cerebral Protection System. The device protects against stroke during transcatheter aortic valve replacement (TAVR) by capturing debris dislodged during the procedure.

Pages